MEK inhibitor breakthroughs in Noonan syndrome — the targeted MAPK pathway therapies demonstrating cardiac function improvement in children with severe hypertrophic cardiomyopathy, alongside Novo Nordisk's February 2026 FDA approval of once-weekly Sogroya (somapacitan) for Noonan-associated growth failure — represent the most transformative therapeutic innovations in this...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek